Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Landmark: JnJ told to...

    Landmark: JnJ told to pay Rs 74.5 lakh to patient by CDSCO

    Meghna A SinghaniaWritten by Meghna A Singhania Published On 2019-03-11T12:19:13+05:30  |  Updated On 11 March 2019 12:19 PM IST
    Landmark: JnJ told to pay Rs 74.5 lakh to patient by CDSCO


    This is the first case where M/s Johnson and Johnson has been directed to pay compensation for its faulty ASR hip implants manufactured and imported by M/s DePuy International Limited (now Johnson & Johnson Pvt Ltd).


    New Delhi: Based on the recommendations of the central expert committee and the state-level committee, the Central Drugs Standard Control Organisation (CDSCO) has directed JnJ to pay Rs 74,57,180 to the first patient from Mumbai who received faulty hip implants made by the company.


    This is the first case where M/s Johnson & Johnson has been directed to pay compensation for its faulty ASR hip implants manufactured and imported by M/s DePuy International Limited (now Johnson & Johnson Pvt Ltd).


    Also Read: J&J faulty hip implants: Review for compensation sought



    The CDSCO has directed the compensation to be paid within 30 days from the date of receipt of the order.In November last year, the Union Health Ministry approved a formula for determination of compensation for patients who had received, prior to August 2010, ASR hip implants manufactured by DePuy International Limited, U.K of J&J.


    Also Read: Compensation formula unacceptable, done without due consultations, say patients of faulty JJ implant



    According to the formula, thousands of patients implanted with US pharmaceutical major Johnson and Johnson's (J&J) articular surface replacement (ASR) hip implant were to be compensated between Rs 30 lakh to Rs 1.23 crore.

    The state-level committee had forwarded their recommendation to the Central Expert Committee along with various documents including the disability certificate issued by the Medical Authority, Mumbai, Maharashtra for further necessary action.

    The recommendations received from the state-level committee were examined by the Central Expert Committee in its meeting held on March 8.

    "The Central Expert Committee after examining the documents as well as the recommendation of the state-level committee is of the considered opinion that the patient implanted with faulty ASR Hip Implant on both hips and subsequent revision of left hip is entitled to the financial compensation as per the formula.

    "As per the formula, the central expert committee has recommended for payment compensation of Rupees 74,57,180 to the patient. Based on the recommendations of the central expert committee and the state-level committee, CDSCO has issued direction on March 8 to M/s Johnson & Johnson Pvt. Ltd to pay Rs 74,57,180 to the patient," a statement issued by CDSCO stated.


    Also Read: J&J case: Health Ministry asks ‘victims’ to approach central or state panel



    The company J&J recalled the faulty metal-on-metal ASR hip implants in 2010 globally after studies red-flagged the high rate of revision surgeries.

    The government in 2017 constituted the central expert panel to investigate the complaints about ASR hip implant devices.

    The committee headed by Dr Arun Kumar Agarwal, Ex-Dean and Professor of ENT, Maulana Azad Medical College stated the pharmaceutical giant "suppressed" facts on the harm of surgeries afterwards which was conducted on patients in India using "faulty" hip replacement systems and recommended that they should be compensated.

    Following this in October 2018, the government had constituted the five-member central expert committee to determine the quantum of compensation to be given to the patients which submitted the formula.


    Also Read: J&J hip implants: Affected patients seek clarity on report on compensation

    amount


    articular surface replacementASRASR HelplineASR hip implantCDSCOCentral Drugs Standard Control Organisationcompensationcriminal negligencefaultyfaulty hip implanthealthhealth carehealth insurancehip implantsHIPSimplant devicesimplantedJ P NaddaJ&JJnJJohnsonJohnson & JohnsonJohnson and JohnsonmedicalMinistry of HealthUnion Health Ministry
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Meghna A Singhania
    Meghna A Singhania

      Meghna A Singhania is the founder and Editor-in-Chief at Medical Dialogues. An Economics graduate from Delhi University and a post graduate from London School of Economics and Political Science, her key research interest lies in health economics, and policy making in health and medical sector in the country. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok